Beese Fulmer Investment Management Inc. Acquires 3,967 Shares of Johnson & Johnson $JNJ

Beese Fulmer Investment Management Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 3.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 136,199 shares of the company’s stock after purchasing an additional 3,967 shares during the period. Johnson & Johnson comprises approximately 1.7% of Beese Fulmer Investment Management Inc.’s investment portfolio, making the stock its 14th largest position. Beese Fulmer Investment Management Inc.’s holdings in Johnson & Johnson were worth $25,254,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson during the third quarter worth about $26,000. Clayton Financial Group LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $28,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc lifted its holdings in Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after buying an additional 198 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Wednesday, January 28th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Citigroup boosted their target price on shares of Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $234.87.

Johnson & Johnson Stock Up 0.5%

Johnson & Johnson stock opened at $243.75 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market cap of $587.41 billion, a PE ratio of 22.06, a price-to-earnings-growth ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $251.71. The firm’s 50-day simple moving average is $229.80 and its 200 day simple moving average is $205.27.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the combination of TECVAYLI (teclistamab‑cqyv) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma, supported by Phase‑3 MajesTEC‑3 data showing improved progression‑free and overall survival — a meaningful commercial and clinical win that can expand J&J’s oncology revenue and shift treatment patterns earlier in the therapy line. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU expanded approval of Akeega to include BRCA‑mutated metastatic hormone‑sensitive prostate cancer — label expansion that can broaden addressable market in oncology and supports incremental sales in EMEA. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Management’s presentation at the Barclays Global Healthcare Conference provides updated commentary on pipeline priorities and commercialization plans — useful for tracking execution but not a discrete catalyst by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/valuation pieces and recent share‑price momentum have revived investor attention — this could sustain trading interest but depends on execution and revenue contribution from recent approvals. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Negative Sentiment: Short interest rose ~20.8% in February to ~25.09M shares (≈1.0% of shares), raising the short‑interest ratio to ~2.5 days — a small bearish signal that can add volatility if sentiment turns.
• Negative Sentiment: Two J&J units agreed to pay about $65M to settle a Tracleer antitrust class action — a modest cash cost relative to J&J’s size but a legal/expense item to note. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.